MALAYSIA DIABETES CARE DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

MALAYSIA DIABETES CARE DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The Malaysia Diabetes Care Drugs Market is expected to register a CAGR greater than 3% forecast period, 2022-2027.

Malaysia's Ministry of Health reported 5,809 new COVID-19 cases in 24 hours, comprising 5,782 locally infected and 27 imported cases, increasing the national total to 2,541,147. So far, about 78.4 percent of the Malaysian population has gotten at least one dose of COVID-19 vaccine, with 75.9 percent completely vaccinated. According to the Health Ministry, four out of every ten patients who died from Covid-19 in Malaysia this year had diabetes. Diabetes affects one in every five Malaysians, or around 3.9 million persons aged 18 and up.

The number of young diabetics is increasing. Diabetes is becoming more common in younger individuals, with the number of diabetics aged 18 to 40 more than tripling in the last 15 years. The growing population of diabetics means a greater burden of the illness and its consequences, which include, among other things, heart disease, stroke, blindness, chronic kidney disease, and lower limb amputation.

In reality, underlying comorbidities account for the majority of coronavirus mortality in Malaysia, with diabetes and hypertension leading the list.

In terms of medicines, the insulin category commands a sizable market share. Over 100 million people worldwide use insulin, including all persons with Type 1 diabetes and 10% to 25% of people with Type 2 diabetes. Insulin production is extremely sophisticated, and there are only a few insulin manufacturers on the market. As a result, there is fierce rivalry among these producers, who are continually striving to satisfy the demands of patients by providing the highest-quality insulin.

Key Market TrendsOral-Anti Diabetes Drugs is having the highest market share in 2021

The Oral-Anti Diabetes Drugs segment is expected to increase with a CAGR of over 3.7% during the forecast period, mainly due to the demand from the diabetes population, which was more than 4.2 million by the end of 2022.

Malaysia has the highest diabetes rate in the Western Pacific area and one of the highest in the world, with an annual cost of roughly 600 million US dollars. A variety of variables are contributing to the growing trend, including population increase, population aging, urbanization, and rising obesity and physical inactivity rates. The growing prevalence of diabetes and its effects in Malaysia prompted this study to comprehensively identify, describe, and quantify Malaysia's pooled prevalence of diabetes and prediabetes. Insulin therapy is the most potent hypoglycaemic medication currently available for diabetes treatment; however, the potency of insulin deteriorates if it is stored under improper conditions. In Malaysia, NCDs including diabetes account for more than 70% of all deaths. Obesity leads to a more than seven times increase in the risk of developing type 2 diabetes while being overweight increases the risk by three times

Through malaysia government encouragement, the usage of Management Devices increased over the forecast period.

Increasing Diabetes population in Malaysia

Diabetes and prediabetes are on the rise in Malaysia, hence the Malaysian government is implementing diabetes prevention and management programs throughout the country. To minimize the prevalence of diabetes in the country, the Malaysian government should develop a comprehensive approach and plan to enhance diabetes knowledge, control, prevention, and treatment. Being overweight and obese are major contributors to Malaysia's younger diabetic population. According to a recent NHMS, one in every two adults in Malaysia is overweight or obese. Diabetes patients have excessive levels of glucose or sugar in their blood. It is a condition caused by the body's inability to produce enough insulin to manage blood sugar levels. It can also be caused by the body's inefficient utilization of insulin, which is known as insulin resistance. Obesity, bad eating habits, sedentary lifestyles, and heredity are all factors that contribute to this process. According to current figures from the ministry's National Diabetes Registry (NDR), 84% of diabetic patients in Malaysia are overweight, with young Malaysians aged 18 to 40 being among them. The ministry is now investigating the Sama-Sama program, which aims to empower family members and caregivers to offer support for persons living with diabetes to enhance disease control and outcomes. The ministry is collaborating with the commercial sector on the program to train healthcare personnel and, subsequently, carers.

Thus, owing to the above factors it is expected to drive the market growth over the forecast period.

Competitive Landscape

The diabetes drugs market is moderately fragmented, with few significant and generic players. The insulin drugs and Sglt-2 drugs market are dominated by a few major players, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, to increase their market shares, players are tapping into new markets, especially emerging economies where the demand is very high compared to the supply.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.